【摘要】 目的探讨异环磷酰胺(IFO)联合长春瑞滨(VRL)治疗对铂类耐药的复发和/或转移的鼻咽癌的疗效和毒副反应。方法VRL25mg/m2,静脉推注,第1,5天;IFO1200mg/m2,静脉滴注3h,第1￣5天;美斯纳400mg,静脉推注,IFO开始后0,3,6h。21d为1疗程,至少完成2周期作疗效评价。结果25例患者中,完全缓解(CR)2例,部分缓解(PR)12例,总有效(CR+PR)率为56.0%,稳定8例,临床获益率(CBR)为88.0%;疾病进展3例;中位疾病进展时间(TTP)为7.1个月(范围2.0～21.0个月),1年生存率为55%。主要毒副反应为骨髓抑制和静脉炎。结论IFO联合VRL治疗对铂类耐药的复发和/或转移的鼻咽癌疗效可靠,毒副反应可耐受。更多还原

【Abstract】 Objective To study the effectiveness and toxicity of ifosfamide(IFO) combined with venorelbine(VRL) in patients with nasopharyngeal carcinoma(NPC) refractory to platinum based chemotherapy. Methods The chemotherapy protocol consisted of intravenous infusion of IFO at the dose of 1200 mg/m2 from day 1 to day 5 with uroprotection of Mesna in infusion at 0,3,6 hours following initiation of IFO and VRL at the dose of 25 mg/m2 at day 1 and day 5. The protocol was repeated every 3 weeks. All patients received at least 2 cycles of chemotherapy. Results Among 25 patients enrolled into the study, 2 patients achieved complete remission, 12 patients achieved partial remission with an total remission rate of 56.0 % and 8 patients had stable disease with clinical benefit rate of 88.0 %. 3 patients had disease progression. Median time to progression was 7.1 months(range:2.0～21.0 months) and 1-year survival rate was 55 %. The main toxicities were myelotoxicity and phlebitis. Conclusion The results indicate that IFO combined with VRL in patients with NPC refractory to platinum based chemotherapy has moderate activity ascompany with tolerable toxicities.更多还原